<DOC>
	<DOCNO>NCT00974012</DOCNO>
	<brief_summary>This study design compare relative bioavailability ( rate extent absorption ) Divalproex Sodium ER Tablets 500 mg DepakoteÂ® ER Tablets 500 mg follow single , oral dose ( 1 x 500 mg extend release tablet ) administer healthy , adult subject non-fasting condition .</brief_summary>
	<brief_title>Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Inclusion Criteria Subjects complete screen process within 28 day prior Period 1 dose Subjects healthy adult men woman 18 year age old time dose . Subjects body mass index ( BMI ) 1930 kg/m2 , inclusive , weigh least 110 lb . Subjects healthy document medical history , physical examination ( include bur may limit evaluation cardiovascular , gastrointestinal , respiratory central nervous system ) , vital sign assessment , 12lead electrocardiogram ( ECG ) , clinical laboratory assessment , general observation . Any abnormalities/deviations normal range might consider clinically relevant study physician investigator evaluate individual case , document study file agree upon study physician investigator prior enrol subject study continue enrollment . Female subject postmenopausal ( menses ) status least 1 year serum FSH level great equal 30 mIU/mL surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) . Exclusion Criteria Subjects report receive investigational drug within 30 day prior Period 1 dosing . Subjects report presence history clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease determine clinical investigator ( ) . Subjects whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Subjects demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody . Subjects report history allergic response ( ) divalproex relate drug . Subjects report use systemic prescription medication 14 day prior Period 1 dosing . Subjects report use drug know induce inhibit hepatic drug metabolism 28 day prior Period 1 dosing . Subjects report history clinically significant allergy include drug allergy . Subjects report clinically significant illness 4 week prior Period 1 dosing ( determined clinical investigator ) . Subjects report history drug alcohol addiction abuse within past year . Subjects demonstrate positive drug abuse screen study prior Period 1 administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>